A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Authors

  • Sergio Iannazzo SIHS Health Economics Consulting, Turin - Italy
  • Chiara Distante SIHS Health Economics Consulting, Turin - Italy
  • Stefania Lopatriello SIHS Health Economics Consulting, Turin - Italy
  • Roberto Bordonaro U.O.C. Oncology Department, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania - Italy

DOI:

https://doi.org/10.33393/grhta.2017.398

Keywords:

Bevacizumab, Colorectal cancer, Cost analysis

Abstract

Introduction Bevacizumab is a monoclonal antibody, which, in association with combination chemotherapy regimens, has been shown to be active in metastatic colorectal cancer. Other biologic agents active in the same setting are cetuximab and panitumumab, both of which are monoclonal antibodies directed against the antiepidermal growth factor receptor. The objective of this study was to compare treatment costs of first-line regimens for metastatic colorectal cancer in Italy. Methods A set of first-line regimens was considered, according to the Italian Association of Medical Oncology and the European Society for Medical Oncology guidelines. A targeted review of the literature was undertaken to identify clinical study references for treatment regimens. The total cost of a regimen was calculated in the perspective of the Italian healthcare system summing up drugs, administration, and adverse event costs, based on year 2016 prices and tariffs. Results Bevacizumab 7.5 mg + capecitabine was the least expensive regimen, with a total cost of €16,754 per patient. When we consider regimens based on FOLFOX, bevacizumab 5 mg + FOLFOX4 was the least expensive (€32,709 per patient), compared to panitumumab + FOLFOX4 (€42,815), cetuximab + FOLFOX4 (€42,725), and cetuximab + FOLFOX (€37,995). If we consider combination regimens based on FOLFIRI, the association of FOLFIRI and bevacizumab was less expensive than regimens that included cetuximab (€28,389 for bevacizumab 5 mg + FOLFIRI and €35,310 for cetuximab + FOLFIRI). Conclusions From the perspective of the Italian health care system, bevacizumab appears to be a convenient option among the first-line regimens for metastatic colorectal cancer. Further study, based on real-world evidence, would be necessary to confirm this result.

Downloads

Published

2017-10-23

How to Cite

1.
Iannazzo S, Distante C, Lopatriello S, Bordonaro R. A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy. Grhta [Internet]. 2017 Oct. 23 [cited 2022 Oct. 1];4(1):221-6. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/398

Issue

Section

Original Research Articles